Neumora Therapeutics (NMRA) Operating Leases (2022 - 2026)

Neumora Therapeutics (NMRA) posted quarterly Operating Leases of $119000.0 for Q1 2026, down 38.34% quarter-over-quarter from $193000.0 in Q4 2025.

Neumora Therapeutics (NMRA) Operating Leases (2022 - 2026) Analysis & Trends

Neumora Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $119000.0 for Q1 2026.

In Q1 2026, Operating Leases changed N/A year-over-year to $119000.0; the TTM figure through Mar 2026 stood at $119000.0 (changed N/A YoY), while the FY2025 annual figure was $193000.0, changed N/A from the prior year.
Operating Leases for Q1 2026 stood at $119000.0, down from $193000.0 in the prior quarter.
The five-year high for Operating Leases was $5.1 million in Q4 2022, with the low at $119000.0 in Q1 2026.
The 5-year median for Operating Leases is $638500.0 (2024), against an average of $1.4 million.
Peak annual rise in Operating Leases reached 63.47% in 2023, while the deepest fall reached 63.47% in 2023.
Neumora Therapeutics' Operating Leases stood at $5.1 million in 2022, then slumped by 63.47% to $1.9 million in 2023, then tumbled by 49.38% to $938000.0 in 2024, then slumped by 79.42% to $193000.0 in 2025, then sank by 38.34% to $119000.0 in 2026.
Business Quant data shows NMRA's Operating Leases at $119000.0 in Q1 2026, $193000.0 in Q4 2025, and $267000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Neumora Therapeutics	296.45 Mn	296.45 Mn	-

Download Data